RTP Mobile Logo
Inside the Issue: Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer (Faculty Presentation)
Released September 2023

Featuring a slide presentation and related discussion from Dr Neal D Shore. Published September 1, 2023. (Faculty Presentation)

CE Information and Faculty Disclosures

    This program is intended for medical and radiation oncologists, nurses, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of nonmetastatic prostate cancer.


    • Employ available risk-classification models to estimate the likelihood of recurrence for patients with newly diagnosed localized or locally advanced prostate cancer, and use this information to refine or individualize treatment plans.
    • Recall current treatment guidelines on the selection of primary therapy for prostate cancer, and identify patients appropriate for radical prostatectomy versus radiation therapy.
    • Explore published research with androgen deprivation therapy in the (neo)adjuvant setting and in the context of biochemical recurrence after local therapy, and design individual patient treatment plans.
    • Assess available data with treatment intensification using secondary hormonal therapy for patients with high-risk localized or locally advanced prostate cancer, and consider the current and potential role of this strategy.
    • Recall the design of ongoing clinical trials evaluating secondary hormonal agents for high-risk localized or locally advanced prostate cancer in the neoadjuvant and adjuvant settings, and counsel appropriate patients about availability and participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/InsideTheIssue2023/HigherRiskProstate/Presentation/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Neal D Shore, MD
    Medical Director, Carolina Urologic Research Center
    Myrtle Beach, South Carolina

    Consulting Agreements: AbbVie Inc, Accord Healthcare Inc, Alessa Therapeutics Inc, Amgen Inc, Antev Ltd, Arquer Diagnostics, Asieris Pharmaceuticals, Astellas, AstraZeneca Pharmaceuticals LP, Aura Biosciences Inc, Bayer HealthCare Pharmaceuticals, BioProtect Ltd, Boston Scientific Corporation, Bristol Myers Squibb, CG Oncology, Clarity Pharmaceuticals, Dendreon Pharmaceuticals Inc, Exact Imaging, Ferring Pharmaceuticals, FIZE Medical, Foundation Medicine, Genentech, a member of the Roche Group, GenesisCare, ImmunityBio, Incyte Corporation, Invitae, Janssen Biotech Inc, Lantheus, Lilly, MDxHealth, Merck, Minomic International Ltd, Myovant Sciences, Myriad Genetic Laboratories Inc, Nonagen Bioscience, Novartis, Nymox Pharmaceutical Corporation, Pacific Edge, Palette Life Sciences, Pfizer Inc, Photocure, PlatformQ, ProFound Therapeutics, Promaxo, Propella Therapeutics Inc, Protara Therapeutics, Sanofi, Specialty Networks, Telix Pharmaceuticals Limited, Tolmar, UroGen Pharma.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Release date: September 2023
    Expiration date: September 2024

    After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):